GlobalData on MSN6h
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpointsAnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...
Hosted on MSN1h
AnaptysBio Stock Down as Eczema Study Fails to Meet GoalsShares of AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company, plunged 32.8% on Dec. 11 after it announced that the ...
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...
AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...
AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...
San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...
AnaptysBio (ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses ...
Return on Equity (ROE): AnaptysBio's ROE is below industry averages, indicating potential challenges in efficiently utilizing ...
The firm would be buyers on today’s weakness and keeps a Buy rating on AnaptysBio, which it calls “the leader in the checkpoint agonist space.” TipRanks is the most comprehensive data set of ...
Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis ... 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused ...
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be discontinuedAnticipate top-line Phase 2b data in rheumatoid arthritis in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback